DE3382190D1 - Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff. - Google Patents

Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.

Info

Publication number
DE3382190D1
DE3382190D1 DE8383850273T DE3382190T DE3382190D1 DE 3382190 D1 DE3382190 D1 DE 3382190D1 DE 8383850273 T DE8383850273 T DE 8383850273T DE 3382190 T DE3382190 T DE 3382190T DE 3382190 D1 DE3382190 D1 DE 3382190D1
Authority
DE
Germany
Prior art keywords
complex
immunistimulans
immunogenous
vaccine
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8383850273T
Other languages
English (en)
Inventor
Bror Morein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE3382190D1 publication Critical patent/DE3382190D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE8383850273T 1982-10-18 1983-10-13 Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff. Expired - Lifetime DE3382190D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8205892A SE8205892D0 (sv) 1982-10-18 1982-10-18 Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin

Publications (1)

Publication Number Publication Date
DE3382190D1 true DE3382190D1 (de) 1991-04-11

Family

ID=20348235

Family Applications (2)

Application Number Title Priority Date Filing Date
DE8383850273T Expired - Lifetime DE3382190D1 (de) 1982-10-18 1983-10-13 Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.
DE198383850273T Pending DE109942T1 (de) 1982-10-18 1983-10-13 Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE198383850273T Pending DE109942T1 (de) 1982-10-18 1983-10-13 Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.

Country Status (18)

Country Link
US (2) US4578269A (de)
EP (1) EP0109942B1 (de)
JP (1) JPH07112983B2 (de)
AR (1) AR243080A1 (de)
AT (1) ATE61228T1 (de)
AU (1) AU558258B2 (de)
CA (1) CA1243954A (de)
DE (2) DE3382190D1 (de)
DK (1) DK162057C (de)
ES (1) ES526524A0 (de)
FI (1) FI80600C (de)
IE (1) IE57025B1 (de)
MX (1) MX7563E (de)
NO (1) NO163668C (de)
NZ (1) NZ205925A (de)
PT (1) PT77515B (de)
SE (1) SE8205892D0 (de)
ZA (1) ZA837603B (de)

Families Citing this family (295)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804624A (en) * 1982-05-21 1989-02-14 The University Of Tennessee Research Corporation Passive agglutination assay for pseudorabies antibody
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4770874A (en) * 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
SE8402861L (sv) * 1984-05-28 1985-11-29 Stefan Svenson Rening av biologiskt material
NL8403195A (nl) * 1984-10-19 1986-05-16 Nederlanden Staat Immunogene complexen en vaccins die deze bevatten.
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
CA1267087A (en) * 1985-02-14 1990-03-27 Nicolaas Visser Synthetic immunogen
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US4631191A (en) * 1985-06-20 1986-12-23 Biotechnology Research Partners, Ltd. Methods and compositions useful in preventing equine influenza
DE3775783D1 (de) * 1986-01-14 1992-02-20 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4981685A (en) * 1986-03-07 1991-01-01 Utah State University Foundation Bacterial extract vaccines for veterinary application
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
CA1331355C (en) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentation
ZA872203B (en) * 1986-04-28 1988-02-24 New York Blood Center Inc Complex immunogen containing synthetic peptides
JPH0789951B2 (ja) * 1986-06-18 1995-10-04 財団法人阪大微生物病研究会 遺伝子発現産物の精製法
US5374426A (en) * 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
US5026828A (en) * 1987-02-27 1991-06-25 Merck & Co., Inc. Method of purifying recombinant pres-1/S-2/S/S hepatitis B antigen from yeast
US5976839A (en) * 1987-03-13 1999-11-02 Bioenterprises Pty Limited Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules
US4888416A (en) * 1987-03-30 1989-12-19 International Minerals & Chemical Corp. Method for stabilizing somatotropins
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5043158A (en) * 1987-08-21 1991-08-27 Chembiomed, Ltd. Immunogenic compositions containing ordered carriers
US5011915A (en) * 1987-10-26 1991-04-30 Merck & Co., Inc. Process for purifying recombinant hepatitis antigens
ATE118348T1 (de) * 1987-12-04 1995-03-15 Liposome Co Inc Liposome hoher stabilität und verfahren zur herstellung und verwendung.
AU3048689A (en) * 1988-01-13 1989-08-11 University Of North Carolina At Chapel Hill, The Immunogenic peptides
US5039522A (en) * 1988-01-29 1991-08-13 New York Blood Center, Inc. Immunogens containing peptides with an attached hydrophobic tail for adsorption to hepatitis B virus surface antigen
US5885589A (en) * 1988-04-12 1999-03-23 Intervet International B.V. Pasteurella vaccine
DK199588D0 (da) * 1988-04-12 1988-04-12 Nordisk Droge & Kemikalie Vaccine
EP0372056A4 (en) * 1988-05-04 1991-05-15 Dana Farber Cancer Institute Protein micelles
US5071964A (en) * 1988-05-04 1991-12-10 Dana-Farber Cancer Institute, Inc. Protein micelles
GB8818415D0 (en) * 1988-08-03 1988-09-07 Animal Health Inst Vaccine
US6291228B1 (en) 1988-08-03 2001-09-18 Vericore Limited Vaccine
JPH0292996A (ja) * 1988-09-30 1990-04-03 Bror Morein アジュバントおよび脂質を含む複合体
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
CA2065414C (en) * 1989-09-15 2007-05-15 Tse-Wen Chang Treatment of autoimmune disease
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
IT1248075B (it) * 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
GB9200117D0 (en) 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
DE4220653A1 (de) * 1992-06-26 1994-01-13 Boehringer Mannheim Gmbh Verfahren und Mittel zum Nachweis eines Analyten enthaltend glykosidische Tenside
EP0604727A1 (de) * 1992-12-31 1994-07-06 American Cyanamid Company Verbesserte Immunogenizität einer Vakzine durch Inkorporieren eines Zytokines in einen immun-stimulierenden Komplex, der ein Antigen enthält
ATE236252T1 (de) * 1993-09-03 2003-04-15 Univ Mcgill Differentiell exprimierte leishmania gene und proteinen
US5773011A (en) * 1993-09-27 1998-06-30 Gerbu Biotechnik Gmbh Method of preparing a synergistic immunological adjuvant formulation
GB9320597D0 (en) * 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
US6083513A (en) * 1993-11-16 2000-07-04 Gerbu Biotechnik Gmbh Method for increasing the yield of antibodies in the techniques of immunology
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU4369596A (en) * 1994-11-21 1996-06-17 Virginia L. Scofield Sperm as vaccine vectors
JPH10512758A (ja) * 1995-01-27 1998-12-08 ジェネンコア インターナショナル インコーポレーテッド 界面活性剤に基づく抽出法
SK282004B6 (sk) 1995-06-07 2001-10-08 Pfizer Inc. Použitie živých sporozoitov alebo merozoitov rodu eimeria na výrobu očkovacej látky na in ovo očkovanie domestikovaných vtákov proti kokcidióze
ES2158108T3 (es) * 1995-06-07 2001-09-01 Pfizer Vacunacion in ovo contra la coccidiosis.
ZA97452B (en) 1996-01-25 1997-08-15 Trinity College Dublin Streptococcus equi vaccine.
GB9618119D0 (en) * 1996-08-30 1996-10-09 Univ Southampton Adjuvants for use in vaccines
ZA9710606B (en) * 1996-12-05 1998-06-12 Akzo Nobel Nv Non-virulent Mycoplasma synoviae vaccine thereof.
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
US6627205B2 (en) 1997-12-01 2003-09-30 Pfizer Incorporated Ovo vaccination against coccidiosis
US6495140B1 (en) 1998-01-12 2002-12-17 Her Majesty In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Canada Process for the isolation, recovery and purification of non-polar extractives
US6908770B1 (en) * 1998-07-16 2005-06-21 Board Of Regents, The University Of Texas System Fluid based analysis of multiple analytes by a sensor array
US20010033839A1 (en) * 1999-10-04 2001-10-25 Emilio Barbera-Guillem Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
US7776343B1 (en) * 1999-02-17 2010-08-17 Csl Limited Immunogenic complexes and methods relating thereto
US6984378B1 (en) 1999-02-26 2006-01-10 Pfizer, Inc. Method for the purification, recovery, and sporulation of cysts and oocysts
CN1351653A (zh) 1999-04-09 2002-05-29 法玛西雅厄普约翰美国公司 抗细菌疫苗组合物
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
DE60014076T2 (de) 1999-04-19 2005-10-13 Glaxosmithkline Biologicals S.A. Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
EP1214054B1 (de) * 1999-09-24 2007-10-31 GlaxoSmithKline Biologicals S.A. Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
DE60039715D1 (de) * 1999-11-19 2008-09-11 Csl Ltd Hcv-impfstoff zusammensetzungen
WO2001070247A2 (en) 2000-03-17 2001-09-27 Pharmacia & Upjohn Company Salmonella vaccine materials and methods
EP1360315A2 (de) 2000-04-06 2003-11-12 PHARMACIA & UPJOHN COMPANY Antimikrobische verfahren und stoffe
US7323174B1 (en) 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon
US20050019340A1 (en) * 2000-10-18 2005-01-27 Nathalie Garcon Vaccines
IL155282A0 (en) * 2000-10-18 2003-11-23 Glaxosmithkline Biolog Sa Vaccines
DK1361890T3 (da) 2001-02-23 2011-06-27 Glaxosmithkline Biolog Sa Influenzavaccineformuleringer til intradermal indgift
JP2004528321A (ja) 2001-04-04 2004-09-16 ノルディック ワクチン テクノロジー アクティーゼルスカブ ステロールおよびサポニンを含むポリヌクレオチド結合複合体
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
CN103394108B (zh) 2001-08-30 2016-06-15 浩卫制药独资有限责任公司 制备卵囊的改进方法
WO2013034682A1 (en) 2011-09-08 2013-03-14 Umc Utrecht Holding B.V. Vaccine based on staphylococcal superantigen- line 3 protein (ssl3)
SE0202110D0 (sv) * 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
JP2005535350A (ja) 2002-08-12 2005-11-24 アクゾ・ノベル・エヌ・ベー ストレプトコッカス・ユベリス蛋白質、前記蛋白質をコードする核酸配列及び乳腺炎ワクチンにおけるその使用
EP2353608B1 (de) 2002-10-11 2019-12-18 Novartis Vaccines and Diagnostics S.r.l. Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
US7125425B2 (en) * 2002-10-21 2006-10-24 Sdgi Holdings, Inc. Systems and techniques for restoring and maintaining intervertebral anatomy
US7491395B2 (en) 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
WO2004045641A2 (en) 2002-11-20 2004-06-03 Crucell Holland B.V. Antigen-complexes
ES2411080T3 (es) 2003-01-30 2013-07-04 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
TWI329130B (en) 2003-06-19 2010-08-21 Bestewil Holding Bv Functionally reconstituted viral membranes containing adjuvant
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
GB0315323D0 (en) 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
ES2505695T3 (es) 2003-07-31 2014-10-10 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunógenas para Streptococcus pyogenes
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
PT1670506E (pt) 2003-10-02 2013-01-28 Novartis Ag Vacinas líquidas para serogrupos meningocócicos múltiplos
US20080254065A1 (en) 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
PL1740217T3 (pl) 2004-04-30 2012-03-30 Novartis Ag Szczepienie koniugatem meningokokowym
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
JP4896021B2 (ja) 2004-05-21 2012-03-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 呼吸器系病原体ワクチンのためのアルファウイルスベクター
WO2005117958A1 (en) 2004-05-28 2005-12-15 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
JP2008506789A (ja) * 2004-07-18 2008-03-06 シーエスエル、リミテッド インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
CA2575548A1 (en) 2004-07-29 2006-07-27 John L. Telford Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
DK3312272T3 (da) 2004-10-08 2019-12-02 Us Gov Health & Human Services Modulering af replikationstilpasning ved brug a mindre optrædende synonyme kodoner
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CA2592627C (en) 2005-01-20 2014-02-25 Isconova Ab Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
WO2006089264A2 (en) 2005-02-18 2006-08-24 Novartis Vaccines And Diagnostics Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
CN101203529A (zh) 2005-02-18 2008-06-18 诺华疫苗和诊断公司 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
EP1896067B1 (de) 2005-06-16 2011-07-20 Universiteit Gent Impfstoffe zur immunisierung gegen helicobacter
CN103550768B (zh) 2005-07-28 2016-01-20 硕腾服务有限责任公司 疫苗施用方法、新猫杯状病毒、及抗猫细小病毒和猫疱疹病毒的动物免疫方法
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
KR20110126726A (ko) 2005-10-07 2011-11-23 화이자 프로덕츠 인코포레이티드 개과 동물의 인플루엔자의 치료를 위한 백신 및 방법
US20110223197A1 (en) 2005-10-18 2011-09-15 Novartis Vaccines And Diagnostics Inc. Mucosal and Systemic Immunization with Alphavirus Replicon Particles
PL1945252T3 (pl) 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP3470080A1 (de) 2005-12-22 2019-04-17 GlaxoSmithKline Biologicals S.A. Impfstoff
EP3753574A1 (de) 2006-01-27 2020-12-23 Seqirus UK Limited Influenzaimpfstoffe mit hämagglutinin und matrixproteinen
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
ES2388556T3 (es) 2006-03-23 2012-10-16 Novartis Ag Compuestos inmunopotenciadores
US20100068223A1 (en) 2006-03-24 2010-03-18 Hanno Scheffczik Storage of Influenza Vaccines Without Refrigeration
US20100021503A1 (en) 2006-03-30 2010-01-28 Glaxosmithkline Biologicals S.A. Immunogenic composition
EP2382988A1 (de) 2006-03-31 2011-11-02 Novartis AG Kombinierte mukosale und parenterale Immunisierung gegen HIV
PL2054431T3 (pl) 2006-06-09 2012-07-31 Novartis Ag Konformery adhezyn bakteryjnych
CN101479293A (zh) 2006-06-29 2009-07-08 诺华有限公司 脑膜炎奈瑟球菌多肽
MX2009000650A (es) 2006-07-18 2009-07-02 Secretary Of The Army The Unit Vacunas para malaria.
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
US8323664B2 (en) 2006-07-25 2012-12-04 The Secretary Of State For Defence Live vaccine strains of Francisella
EP2064230A2 (de) 2006-08-16 2009-06-03 Novartis AG Immungene aus uropathogenen escherichia coli
KR20090057015A (ko) 2006-09-11 2009-06-03 노파르티스 아게 난을 사용하지 않는 인플루엔자 바이러스 백신의 제조
ES2673046T3 (es) 2006-09-26 2018-06-19 Infectious Disease Research Institute Composición de vacuna que contiene un adyuvante sintético
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CN101553252A (zh) 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
EP3300743B1 (de) 2006-12-27 2023-06-14 Zoetis Services LLC Verfahren zur verabreichung eines impfstoffes
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
US20110097360A1 (en) 2007-05-25 2011-04-28 Claudio Donati Streptococcus pneumoniae pilus antigens
CN101784282B (zh) 2007-06-26 2015-07-08 葛兰素史密丝克莱恩生物有限公司 包含肺炎链球菌荚膜多糖缀合物的疫苗
EP2484377A1 (de) 2007-06-27 2012-08-08 Novartis AG Influenza Impfstoffe mit wenig Zusatzstoffen
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CN101969992B (zh) 2007-09-12 2014-10-01 诺华股份有限公司 Gas57突变型抗原和gas57抗体
EP2062594A1 (de) 2007-11-21 2009-05-27 Wyeth Farma, S.A. Impfstoff und immunogene Zusammensetzung gegen den Blauzungenvirus, Verfahren zu deren Verwendung und Verfahren zu deren Herstellung
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP3118213A1 (de) 2007-12-19 2017-01-18 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Lösliche formen von hendra- und nipah-virus-f-glycoprotein und anwendungen davon
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CN104292312A (zh) 2007-12-21 2015-01-21 诺华股份有限公司 链球菌溶血素o的突变形式
SI2222710T1 (sl) 2007-12-24 2016-11-30 Id Biomedical Corporation Of Quebec Rekombinatni RSV antigeni
RU2475496C2 (ru) 2008-02-21 2013-02-20 Новартис Аг МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP
EA201071086A1 (ru) 2008-03-18 2011-04-29 Новартис Аг Усовершенствованный способ получения вакцинных антигенов вируса гриппа
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
JP2012515157A (ja) 2009-01-12 2012-07-05 ノバルティス アーゲー グラム陽性細菌に対するワクチンにおけるＣｎａ＿Ｂドメイン抗原
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
WO2010094663A1 (en) 2009-02-17 2010-08-26 Glaxosmithkline Biologicals S.A. Inactivated dengue virus vaccine with aluminium-free adjuvant
EP2403526B1 (de) 2009-03-06 2019-05-15 GlaxoSmithKline Biologicals SA Chlamydia-antigene
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
BRPI1013780B8 (pt) 2009-04-14 2022-10-04 Novartis Ag Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
DK2442826T3 (en) 2009-06-15 2015-09-21 Univ Singapore Influenza vaccine, composition and methods of using
CN102548578A (zh) 2009-06-24 2012-07-04 魁北克益得生物医学公司 疫苗
CN102481359B (zh) 2009-06-24 2015-08-19 葛兰素史密斯克莱生物公司 重组rsv抗原
CN102470168A (zh) * 2009-07-10 2012-05-23 伊斯克诺瓦公司 新组合物
BR112012001666A2 (pt) 2009-07-15 2019-09-24 Novartis Ag composições de proteína rsv f e métodos para fazer as mesmas
WO2011007257A1 (en) 2009-07-16 2011-01-20 Novartis Ag Detoxified escherichia coli immunogens
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP2013502918A (ja) 2009-08-27 2013-01-31 ノバルティス アーゲー 髄膜炎菌ｆＨＢＰ配列を含むハイブリッドポリペプチド
US20110110980A1 (en) 2009-09-02 2011-05-12 Wyeth Llc Heterlogous prime-boost immunization regimen
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
WO2011138636A1 (en) 2009-09-30 2011-11-10 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
CN102724988B (zh) 2009-09-30 2014-09-10 诺华股份有限公司 脑膜炎球菌fHBP多肽的表达
BR112012009309B1 (pt) 2009-10-19 2021-10-05 Intervet International B.V Vacina combinada, uso de células de microrganismos,método para a preparação de uma vacina combinada, e, kit de partes
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
JP2013507944A (ja) 2009-10-22 2013-03-07 ウニヴェルシテート・ライプツィヒ 汎血球減少症罹患仔ウシにおけるサーコウイルス（ｃｉｒｃｏｖｉｒｕｓ）の特定
WO2011051893A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
WO2011117408A1 (en) 2010-03-26 2011-09-29 Glaxosmithkline Biologicals S.A. Hiv vaccine
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
EP2558069A1 (de) 2010-04-13 2013-02-20 Novartis AG Benzonapthyridinzusammensetzungen und ihre verwendung
EP2560985B1 (de) 2010-04-21 2016-06-29 Pharmaq AS Nukleinsäuresequenzen eines fischvirus und ihre verwendung
CN107641151B (zh) 2010-05-14 2021-10-01 百深公司 Ospa嵌合体及其在疫苗中的用途
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
CA2802756C (en) * 2010-06-24 2021-05-04 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
WO2012010290A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
CN103052401A (zh) 2010-07-23 2013-04-17 伊斯克诺瓦公司 流感疫苗
US8628947B2 (en) 2010-08-30 2014-01-14 Intervet Inc. Potomac horse fever isolates
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
CN103228294A (zh) 2010-09-27 2013-07-31 葛兰素史密斯克莱生物公司 疫苗
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
WO2012059592A1 (en) 2010-11-05 2012-05-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compounds for delivering a therapeutic or imaging agent to the brain
WO2012066481A1 (en) 2010-11-15 2012-05-24 Pharmaq As New ethiological agent
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
BR112013014302A2 (pt) 2010-12-08 2016-09-20 Neovacs vacina fortemente inativada e ainda altamente imunogênica e processo de fabricação da mesma
EP2462950A1 (de) 2010-12-08 2012-06-13 Neovacs Stark inaktivierter und weiterhin hoch immunogener Impfstoff, sowie Verfahren zu seiner Herstellung
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
EP2658866B1 (de) 2010-12-29 2016-05-25 Intervet International B.V. Salmonid-alphavirusprotein e2
BR112013016694A2 (pt) 2010-12-29 2018-05-22 Intervet Int Bv ácido nucleico isolado, microrganismo carregador recombinante vivo. anticorpo monocolonal, vacina para caninos contra babesiose, método para a preparação de vacina, uso de polipeptídeo ou fragmento imunogêncio do mesmo, e, kit de teste de diagnóstico
US9506933B2 (en) 2011-01-07 2016-11-29 Toagosei Co., Ltd. Method of preparing antigen for acquiring anti-hydrophobic peptide antibody
ES2727836T3 (es) 2011-01-26 2019-10-21 Glaxosmithkline Biologicals Sa Régimen de inmunización del VRS
EP2691111B1 (de) 2011-03-31 2017-09-20 Institut National de la Sante et de la Recherche Medicale (INSERM) Verwendung von bacteriome aus blut oder gewebe für vorhersage, diagnose und prävention von stoffwechselkrankheiten und ihre kardiovaskulären komplikationen
RU2639135C2 (ru) 2011-04-07 2017-12-19 Неовакс СПОСОБ ЛЕЧЕНИЯ СВЯЗАННЫХ С IFN-альфа СОСТОЯНИЙ
EP2508197A1 (de) 2011-04-07 2012-10-10 Neovacs Verfahren zur Behandlung IFN-alpha-assoziierter Erkrankungen
ES2782119T3 (es) 2011-05-13 2020-09-10 Glaxosmithkline Biologicals Sa Antígenos de F de prefusión del VRS
CA2836098C (en) 2011-05-13 2022-06-21 Zoetis Llc Hendra and nipah virus g glycoprotein immunogenic compositions
JP2014522842A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用
EP2729168A2 (de) 2011-07-06 2014-05-14 Novartis AG Immunogene zusammensetzungen und ihre verwendungen
EP2729178A1 (de) 2011-07-08 2014-05-14 Novartis AG Tyrosinverbindungsverfahren
WO2013038375A2 (en) 2011-09-14 2013-03-21 Novartis Ag Methods for making saccharide-protein glycoconjugates
PT2750683T (pt) 2011-10-03 2018-06-26 Mx Adjuvac Ab Nanopartículas, processo de preparação e seu uso como transportadores para moléculas hidrofóbicas anfipáticas no domínio da medicina, incluindo tratamento de cancro e compostos relacionados a alimentos
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
EP3744343A1 (de) 2011-11-23 2020-12-02 In3Bio Ltd. Rekombinante proteine und deren therapeutische verwendungen
BR112014013224B1 (pt) 2011-11-30 2023-03-07 Emory University Inibidores de jak antivirais úteis no tratamento ou prevenção de infecções retrovirais e outras infecções virais
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
PT2811981T (pt) 2012-02-07 2019-06-12 Infectious Disease Res Inst Formulações adjuvantes melhoradas que compreendem os agonistas de tlr4 e os seus métodos de utilização
CN107540730B (zh) 2012-05-16 2021-07-16 免疫设计公司 用于hsv-2的疫苗
JP2015518845A (ja) 2012-05-22 2015-07-06 ノバルティス アーゲー 髄膜炎菌血清群ｘコンジュゲート
US9370182B2 (en) 2012-05-28 2016-06-21 Toagosei Co., Ltd. Antimicrobial peptide and use thereof
EP2869842A1 (de) 2012-07-06 2015-05-13 Novartis AG Immunogene zusammensetzungen und verwendungen davon
EP2877206B1 (de) 2012-07-27 2019-11-27 Baxalta GmbH Zusammensetzungen mit chimären ospa-molekülen und verfahren zu ihrer verwendung
CA2879939A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Novel method
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
WO2014043189A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes viruses and use thereof in vaccines
RU2662970C2 (ru) 2012-09-18 2018-07-31 Новартис Аг Везикулы наружной мембраны
CA2883481A1 (en) 2012-10-03 2014-04-10 Novartis Ag Immunogenic compositions
WO2014061749A1 (ja) 2012-10-18 2014-04-24 東亞合成株式会社 ２型ｔｎｆ受容体の発現を抑制する合成ペプチド及びその利用
ES2656510T3 (es) 2012-11-30 2018-02-27 Glaxosmithkline Biologicals S.A. Antígenos de Pseudomonas y combinación de antigenos
UY35418A (es) 2013-03-15 2014-10-31 Glaxosmithkline Biolog Sa Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
MY187936A (en) 2013-03-15 2021-10-29 In3Bio Ltd Self-assembling synthetic proteins
US10294277B2 (en) 2013-03-26 2019-05-21 The Pirbright Institute Stabilised FMDV capsids
WO2014163558A1 (en) 2013-04-01 2014-10-09 Moreinx Ab Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
EA032326B1 (ru) 2013-04-18 2019-05-31 Иммьюн Дизайн Корп. Монотерапия gla для применения в лечении рака
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US20160193322A1 (en) 2013-08-05 2016-07-07 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
BR112016007919A2 (pt) 2013-10-11 2017-12-05 Fund Profesor Novoa Santos vacinas atenuadas vivas
EP2870974A1 (de) 2013-11-08 2015-05-13 Novartis AG Salmonella-Konjugatimpfstoffe
JP2017501162A (ja) 2013-12-16 2017-01-12 ゾエティス・サービシーズ・エルエルシー ヘンドラ及びニパウイルスｇ糖タンパク質免疫原性組成物
KR102411781B1 (ko) 2013-12-31 2022-06-22 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 단일 바이알 백신 제형
LT3122378T (lt) 2014-03-26 2020-02-10 Glaxosmithkline Biologicals S.A. Mutantų stafilokokiniai antigenai
WO2015164826A2 (en) 2014-04-24 2015-10-29 Rhode Island Hospital ASPARTATE-β-HYDROXYLASE INDUCES EPITOPE-SPECIFIC T CELL RESPONSES IN TUMORS
EP3888676A1 (de) 2014-06-13 2021-10-06 GlaxoSmithKline Biologicals S.A. Immunogene kombinationen
US10759836B2 (en) 2014-07-18 2020-09-01 University Of Washington Cancer vaccine compositions and methods of use thereof
US9790509B2 (en) 2014-07-18 2017-10-17 Oregon Health & Science University 5′-triphosphate oligoribonucleotides
CN104250640A (zh) 2014-08-22 2014-12-31 普莱柯生物工程股份有限公司 猪伪狂犬病病毒基因缺失株、疫苗组合物及其制备方法和应用
WO2016034610A1 (en) 2014-09-03 2016-03-10 Intervet International B.V. Attenuated bovine coronavirus and related vaccines
CN106794242B (zh) 2014-10-03 2021-11-30 英特维特国际股份有限公司 针对禽类呼肠孤病毒的广谱疫苗
WO2016059161A1 (en) 2014-10-15 2016-04-21 Xenothera Composition with reduced immunogenicity
US10813993B2 (en) 2015-03-03 2020-10-27 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Display platform from bacterial spore coat proteins
CN111560355A (zh) 2015-03-20 2020-08-21 普莱柯生物工程股份有限公司 一种猪伪狂犬病病毒致弱方法、及其致弱的病毒株、疫苗组合物和应用
JP6886410B2 (ja) 2015-06-10 2021-06-16 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 核酸含有組成物の作製および精製のためのプロセス
EP3344291A4 (de) 2015-09-03 2019-04-10 Novavax, Inc. Impfstoffzusammensetzungen mit verbesserter stabilität und immunogenität
CN105770887A (zh) * 2016-03-04 2016-07-20 邓招红 一种用于hbv疫苗的佐剂及其制备方法
GB2551984B (en) 2016-06-30 2019-01-16 Pharmaq As Fish virus
EP3500292A1 (de) 2016-08-17 2019-06-26 Pharmaq AS Seelaus-impfstoff
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
WO2018109220A2 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
CA3070034A1 (en) 2017-07-18 2019-01-24 In3Bio Ltd. Synthetic proteins and therapeutic uses thereof
AU2018330165A1 (en) 2017-09-08 2020-04-02 Access To Advanced Health Institute Liposomal formulations comprising saponin and methods of use
AU2019238171A1 (en) 2018-03-19 2020-09-24 Novavax, Inc. Multivalent influenza nanoparticle vaccines
EP3581201A1 (de) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 polypeptide und verwendungen davon
EP3840770A1 (de) 2018-08-23 2021-06-30 GlaxoSmithKline Biologicals SA Immunogene proteine und zusammensetzungen
KR20220125149A (ko) 2019-05-25 2022-09-14 액세스 투 어드밴스드 헬스 인스티튜트 애주번트 백신 에멀션을 분무 건조시키기 위한 조성물 및 방법
AU2020301638A1 (en) 2019-06-25 2022-02-17 In3Bio Ltd. Stabilized chimeric synthetic proteins and therapeutic uses thereof
EP4058581A1 (de) 2019-11-15 2022-09-21 Infectious Disease Research Institute Rig-i-agonist und adjuvans-formulierung zur tumorbehandlung
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
EP3922255A1 (de) 2020-06-10 2021-12-15 Prokarium Limited Krebstherapie
MX2023006320A (es) 2020-12-02 2023-06-14 Glaxosmithkline Biologicals Sa Cadena donante complementada fimh.
EP4267610A1 (de) 2020-12-23 2023-11-01 Xenothera Polyklonale antikörperzusammensetzung aus schwein zur verwendung zur behandlung und/oder vorbeugung der antikörperabhängigen makrophagen-proinflammatorischen zytokinfreisetzung in einer passiven antiinfektiösen immuntherapie
EP4124342A1 (de) 2021-07-28 2023-02-01 Prokarium Limited Krebstherapie mit lebenden attenuierten bakterien
WO2023079528A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
WO2023114727A1 (en) 2021-12-13 2023-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bacteriophage lambda-vaccine system
GB2622559A (en) 2022-05-10 2024-03-27 Johan Frostegaard Compositions, methods and uses
WO2023225458A1 (en) 2022-05-16 2023-11-23 Zoetis Services Llc Vaccines against moritella viscosa
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions
GB202215134D0 (en) 2022-10-13 2022-11-30 Prokarium Ltd Composition
GB202215576D0 (en) 2022-10-21 2022-12-07 Prokarium Ltd Circuit
WO2024130009A1 (en) 2022-12-14 2024-06-20 Yale University Compositions and methods of use thereof for the treatment of virally driven cancers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1083815A (en) * 1963-10-01 1967-09-20 Wellcome Found Vaccine adjuvants
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
US4117113A (en) * 1974-06-25 1978-09-26 National Research Development Corporation Immunological preparations
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US4196191A (en) * 1975-09-29 1980-04-01 Burroughs Wellcome Co. Biological preparations
US4148876A (en) * 1975-09-29 1979-04-10 Burroughs Wellcome Co. Biological preparations
US4201767A (en) * 1978-11-08 1980-05-06 Merck & Co., Inc. Viral liposome particle
US4235877A (en) * 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4261975A (en) * 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4251509A (en) * 1980-01-31 1981-02-17 Wisconsin Alumni Research Foundation Dry particulate vaccine for oral administration
DE3014189A1 (de) * 1980-04-14 1981-10-15 Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren
DE3173713D1 (en) * 1980-09-05 1986-03-20 Frappier Armand Inst Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
CA1206094A (en) * 1981-01-09 1986-06-17 Thomas P. Hopp Synthetic antigenic composition and process for making same
GB2093039B (en) * 1981-01-29 1984-06-06 Nat Res Dev Improvements relating to hepatitis b vaccine
EP0058021A3 (de) * 1981-02-06 1982-10-27 Beecham Group Plc Pharmazeutische Präparate
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin

Also Published As

Publication number Publication date
ES8503951A1 (es) 1985-04-01
IE832394L (en) 1984-04-18
FI833748A0 (fi) 1983-10-14
DE109942T1 (de) 1984-12-06
FI833748A (fi) 1984-04-19
IE57025B1 (en) 1992-03-25
JPH07112983B2 (ja) 1995-12-06
AU558258B2 (en) 1987-01-22
EP0109942A2 (de) 1984-05-30
CA1243954A (en) 1988-11-01
ES526524A0 (es) 1985-04-01
EP0109942B1 (de) 1991-03-06
US4578269A (en) 1986-03-25
ZA837603B (en) 1984-12-24
FI80600C (fi) 1990-07-10
SE8205892D0 (sv) 1982-10-18
NZ205925A (en) 1987-10-30
JPS59186921A (ja) 1984-10-23
PT77515B (en) 1986-04-16
FI80600B (fi) 1990-03-30
DK162057B (da) 1991-09-09
NO833769L (no) 1984-04-24
US4744983A (en) 1988-05-17
NO163668C (no) 1990-07-04
MX7563E (es) 1989-10-17
AU2010383A (en) 1984-05-03
DK478383A (da) 1984-04-19
NO163668B (no) 1990-03-26
ATE61228T1 (de) 1991-03-15
DK162057C (da) 1992-02-10
DK478383D0 (da) 1983-10-17
PT77515A (en) 1983-11-01
AR243080A1 (es) 1993-07-30
EP0109942A3 (en) 1985-08-14

Similar Documents

Publication Publication Date Title
DE3382190D1 (de) Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.
DE68900758D1 (de) Verfahren zur herstellung von zusammengesetzten kaesen.
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
DE3688209D1 (de) Verfahren zur herstellung von kohlenstoffilamenten und durch dieses verfahren erhaltene kohlenstoffilamente.
DE3587360D1 (de) Verfahren zur herstellung von chimaerischen monoklonalen antikoerpern.
DE58904994D1 (de) Verfahren zur herstellung von vinylacetat.
DE68907164D1 (de) Verfahren zur herstellung von allylacetat.
DE3674853D1 (de) Verfahren zur herstellung von insbesondere gewickelten waffeltueten.
DE3880440D1 (de) Verfahren zur herstellung von apoaequorin.
DE3766176D1 (de) Verfahren zur herstellung von tonern.
DE3776601D1 (de) Verfahren zur herstellung von p.l.z.t.-pulver.
DE3381934D1 (de) Verfahren zur herstellung von shampoos.
DE58902137D1 (de) Verfahren zur herstellung von caprolacton.
DE58902220D1 (de) Verfahren zur herstellung von octadienolen.
DE68901908D1 (de) Verfahren zur herstellung von mesophasepech.
DE3485711D1 (de) Immunoadsorbens und verfahren zur zurueckgewinnung von vitamin-k-abhaengigen proteinen mittels dieses adsorbens.
DE68910771D1 (de) Verfahren zur Herstellung von verbessertem Proteinhydrolysat.
DE58902073D1 (de) Verfahren zur herstellung von organohalogensilanen.
DE68904436D1 (de) Verfahren zur herstellung von 1-alkyl-5-nitro-imidazolen.
DE58902242D1 (de) Verfahren zur herstellung von thymol.
DE68903464D1 (de) Verfahren zur herstellung von kaese.
DE3768372D1 (de) Verfahren zur herstellung von aethylenoxid.
DE68905908D1 (de) Verfahren zur herstellung von alkansulfonamiden.
DE68904457D1 (de) Verfahren zur herstellung von alkandiolen.
DE3786870D1 (de) Methode zur herstellung von proteinen.

Legal Events

Date Code Title Description
8380 Miscellaneous part iii

Free format text: DER PATENTINHABER LAUTET RICHTIG: MOREIN, BROR, UPPSALA, SE

8364 No opposition during term of opposition